1. Medtech Insight
  2. >>Business
  3. >>Strategy

Device Firm Earnings: Winners And Losers

In this earnings review, we pick out the high achievers and underperformers from the companies that released quarterly results in the past week. Reports from J&J, ResMed, bioMérieux, St. Jude Medical and more.

Johnson & Johnson (JNJ): Dropping Cordis appears to be working out so far for the massive conglomerate, whose medical device units reported some good news amidst an ongoing restructuring, announced Jan. 16, that will cost about 3,000 jobs. (See [A#01160125002].) Excluding the net impact of acquisitions and divestitures, on an operational basis, Johnson & Johnson’s worldwide medical sales increased 2.5%, domestic sales increased 3.3% and international sales increased 2.0%. Including the impact of divestitures, J&J’s overall 2015 medical devices sales were $25.1 billion for all of 2015, representing an operational revenue decline of 1.4%, driven mainly by a 1.7% operational revenue drop in international markets. During its Jan. 26 earnings call, the company cited strong sales in surgery, orthopedics, electrophysiology and vision care, partially offset by the divestiture of the Cordis business in March. (See Also see "Cardinal Health Builds On Generic Device Strategy With Cordis Deal" - Medtech Insight, 2 March, 2015..)

ResMed Inc. (RMD): The sleep and respiratory device-maker appears to be containing the damage caused by the negative findings...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

 
• By Shubham Singh

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

More from Business

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.